Linezolid as Potent Inhibitor of SARS-CoV-2 Nsp13 Helicase: Grid Based Docking Approach

Abstract

A diversified originator in humans and wildlife, the corona virus (COVID-19) is an enveloped RNA virus. Six different species have been shown to be the root of human sickness. Human diseases are greatly influenced by viral infections, and one of the most recent global epidemics is the appearance of the new corona. The SARS (Severe Acute Respiratory Syndrome) virus, a potentially fatal viral infection, was caused by the SS-RNA virus from the enveloped corona virus family. In many nations around the world, disease is rapidly expanding. 462,684 confirmed cases and 20,834 fatalities had been reported as of March 26, 2020, internationally. On March 11, 2020, COVID-19 was declared a pandemic by the World Health Organization (WHO). There are numerous medication trials ongoing, and some of the outcomes are encouraging. However, since there is no vaccine, the only approach to fight the virus is through preventative measures. Patients with bacterial nosocomial pneumonia were successfully treated with the antibiotic "Linezolid" by receiving an intravenous dose of 600 mg of linezolid every 12 hours for 7 to 10 days. All of the patients made a full recovery and were allowed to leave the hospital. Additionally, previous studies have shown that linezolid is more clinically and microbiologically effective than other antibiotics (vancomycin). The goal of the current study was to use a molecular docking approach to evaluate linezolid's potential against SAR-CoV-2 infection.